Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded PhaseHana M. El Sahly, Jacqueline M. Miller, Frank Eder et al.|New England Journal of Medicine|2021Cited by 661
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trialSpyros Chalkias, Rituparna Das, Frank Eder et al.|Nature Medicine|2022Cited by 144
Phase 3 Trial of mRNA-1273 during the Delta-Variant SurgeLindsey R. Baden, Jacqueline M. Miller, Hana M. El Sahly et al.|New England Journal of Medicine|2021Cited by 63
Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trialK. Rachael Parks, M. Juliana McElrath, Zoe Moodie et al.|Science Translational Medicine|2025Cited by 40
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trialRolando Pajón, F. Schödel, Yamuna Devi Paila et al.|Nature Medicine|2022Cited by 36